Positive opinions recommend approval for mAb in three additional eosinophil-driven diseases
News
New UK partnership aims to help build startup companies focused on cancer
Cancer Research UK has partnered with the University of Edinburgh’s ‘venture builder incubator’
Government review highlights the impact of overprescribing medicines
Review sets out practical and cultural changes to ensure patients get the most appropriate treatments
NHS patients gain access to COVID-19 treatment Ronapreve
Ronapreve will be targeted at hospitalised patients who have not mounted an antibody response against COVID-19
FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
Mirati’s adagrasib scores encouraging results in KRAS-mutated lung cancer
Adagrasib is an investigational oral small-molecule inhibitor of KRAS G12C
Positive topline results for Pfizer/BioNTech jab in five to 11-year-olds
Results showed vaccine has favourable safety profile in this age group
Sanofi/Regeneron’s Libtayo hits the mark in first-line NSCLC
Positive data presented at the 2021 ESMO virtual congress
Enhertu reduces breast cancer disease progression or death by 72%
‘Groundbreaking results’ for the treatment of HER2-positive metastatic breast cancer
Promising early results for new ovarian cancer drug combo
Drug combination could offer a new option for treatment-resistant advanced ovarian cancer
2021 PM Society Digital Awards winners announced
Leading the agency side, Havas Life Medicom came out on top with three Gold award wins
Novartis says its radioligand therapy boosts health-related quality of life
177Lu-PSMA-617 is being evaluated for the treatment of metastatic castration-resistant prostate cancer
Keytruda made available on the NHS for certain oesophageal cancer patients
Approximately 1,000 people will be eligible for the treatment in England
Novavax joins Oxford mix-and-match COVID-19 vaccine study in adolescents
The Phase II clinical trial will include at least 360 adolescents aged 12-16 years old
BioCryst’s HAE med Orladeyo wins NICE nod
NICE has recommended the treatment for people who have at least two attacks per month
